loading...| Preferred Name |
Travoprost |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47766 |
| Accepted_Therapeutic_Use_For |
Glaucoma |
| CAS_Registry |
157283-68-6 |
| CHEBI_ID |
CHEBI:746859 |
| Chemical_Formula |
C26H35F3O6 |
| code |
C47766 |
| Concept_In_Subset | |
| Contributing_Source |
FDA |
| DEFINITION |
A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure. |
| FDA_UNII_Code |
WJ68R08KX9 |
| FULL_SYN |
5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)- AL-6221 Travoprost Travatan Z TRAVOPROST |
| label |
Travoprost |
| Legacy Concept Name |
Travoprost |
| Preferred_Name |
Travoprost |
| prefixIRI |
Thesaurus:C47766 |
| prefLabel |
Travoprost |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C0937916 |
| subClassOf |